MARKET

PRTA

PRTA

Prothena
NASDAQ
66.44
-0.81
-1.20%
After Hours: 66.44 0 0.00% 16:07 05/26 EDT
OPEN
67.38
PREV CLOSE
67.25
HIGH
68.50
LOW
65.54
VOLUME
413.43K
TURNOVER
0
52 WEEK HIGH
79.65
52 WEEK LOW
21.06
MARKET CAP
3.50B
P/E (TTM)
-25.3762
1D
5D
1M
3M
1Y
5Y
Prothena: Report of proposed sale of securities
Press release · 6d ago
Prothena: Initial statement of beneficial ownership of securities
Press release · 05/20 04:07
Prothena: Statement of changes in beneficial ownership of securities
Press release · 05/20 04:07
Prothena: Current report
Press release · 05/19 16:34
Insider Sell: Prothena
Insider Sell: Prothena
MT Newswires · 05/18 00:38
Prothena adds former FDA neuro chief Billy Dunn to director board
Seeking Alpha · 05/17 16:13
Analysts Offer Insights on Healthcare Companies: Prothena (PRTA), Arcutis Biotherapeutics (ARQT) and Theseus Pharmaceuticals (THRX)
TipRanks · 05/17 12:31
BRIEF-Prothena Corporation PLC -Board Of Co Increased Size Of Board & Appointed William H. Dunn, Jr., M.D. To Serve As Director Of Co, Effective Immediately
Reuters · 05/16 20:44
More
About PRTA
Prothena Corporation Public Limited Company is a late-stage clinical company engaged in the protein dysregulation and a pipeline of investigational therapies for rare peripheral amyloid and neurodegenerative diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The Company's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.

Webull offers kinds of Prothena Corporation PLC stock information, including NASDAQ:PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.